| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4003517 | American Journal of Ophthalmology | 2011 | 11 Pages |
Abstract
Discontinuation of anti-CMV therapy after immune recovery did not increase the risk of poor outcomes. These results support the current guidelines for discontinuation of anti-CMV therapy after achievement of sustained immune recovery.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Janet T. Holbrook, Ryan Colvin, Mark L. van Natta, Jennifer E. Thorne, Mark Bardsley, Douglas A. Jabs, Studies of Ocular Complications of AIDS (SOCA) Research Group Studies of Ocular Complications of AIDS (SOCA) Research Group,